螺旋断层放疗大分割影像引导放疗治疗肺部肿瘤的疗效及影像学表现模式
本研究纳入68例医学上不可手术的肺部病变患者(69个病灶),评估螺旋断层放疗(HHT)大分割影像引导放疗的疗效及CT肺损伤模式。中位随访12个月,未发生≥4级放射性肺炎,3级放射性肺炎发生率为5.8%,2例(3%)出现晚期≥3级症状性放射性纤维化,急性和晚期均未显示特定CT肺损伤模式。中位总生存期30.8个月,无进展生存期14.1个月;多因素分析显示BED10≥100 Gy和KPS≥90为总生存期显著预后因素,BED10≥100 Gy为无进展生存期显著预后因素。
要点
- HHT大分割影像引导放疗后急性和晚期CT均未显示特定肺损伤模式。
- 3级放射性肺炎发生率为5.8%,未发生≥4级放射性肺炎,晚期≥3级症状性放射性纤维化2例(3%)。
- 多因素分析显示BED10≥100 Gy和KPS≥90为总生存期显著预后因素(p=0.01和p=0.001)。
核心结论
- HHT根据肿瘤位置和/或靶体积调整的大分割影像引导放疗对医学上不可手术的肺部肿瘤患者是一种有效治疗,毒性可接受,且不伴随特定肺损伤模式;当常规立体定向消融放疗设备不可用时,可作为可行选择。
研究设计与样本
- 研究纳入68例医学上不可手术、无胸外活动性疾病证据的患者(69个病灶),处方剂量由肿瘤位置(肺门/中央型 vs 周围型)和/或靶体积决定,52%的病灶接受BED10≥100 Gy;肿瘤反应依据RECIST 1.1标准结合氟-18脱氧葡萄糖/正电子发射断层扫描-CT评估,毒性依据CTCAE v.4.0监测治疗相关肺部不良事件,急性事件分类为放射性肺炎,晚期事件分类为放射性纤维化;采用Kaplan-Meier法计算生存曲线,采用Cox比例风险模型进行单因素和多因素生存分析。
关键影像表现/征象
- 急性和晚期均未显示特定CT肺损伤模式。
- 未记录到≥4级放射性肺炎。
- 5.8%的患者发生临床严重(3级)放射性肺炎。
- 2例(3%)患者出现晚期严重(≥3级)症状性放射性纤维化。
诊断标准与关键数值
- 肿瘤反应评估基于RECIST 1.1标准结合氟-18脱氧葡萄糖/正电子发射断层扫描-CT。
- 毒性分级依据CTCAE v.4.0,急性事件为放射性肺炎,晚期事件为放射性纤维化。
- 多因素分析显示BED10≥100 Gy和KPS≥90为总生存期显著预后因素(p=0.01和p=0.001)。
- 多因素分析显示BED10≥100 Gy为无进展生存期显著预后因素(p=0.02)。
临床应用与阅片要点
- HHT根据肿瘤位置和/或靶体积调整的大分割影像引导放疗可用于医学上不可手术的肺部肿瘤患者。
- 治疗后急性和晚期CT随访均未显示特定肺损伤模式,影像学评估时应注意此特点。
- 当常规立体定向消融放疗设备不可用时,HHT可作为可行选择。
局限性
- 本研究为单中心研究且样本量小(原文未明示,但摘要中未报告局限性;结论中未提及需进一步研究)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate treatment outcomes and patterns of CT lung injury after hypofractionated image-guided radiotherapy delivered with helical tomotherapy (HHT) in a series of inoperable lung lesions.
METHODS: 68 patients who were medically inoperable (69 lesions) without evidence of viable extrathoracic disease were included. Dose prescription was driven by tumour location (hilar/pericentral vs peripheral) and/or target volume. 52% of the lesions received a biological equivalent dose (BED10) ≥100 Gy. Assessment of tumour response was based on the Response Evaluation Criteria in Solid Tumours 1.1 criteria coupled with fluorine-18 fludeoxyglucose/positron emission tomography-CT. Toxicity monitoring was focused on treatment-related pulmonary adverse events according to the Common Terminology Criteria for Adverse Events v. 4.0. Acute and late events were classified as radiation pneumonitis (RP) and radiation fibrosis (RF), respectively. Survival curves were calculated using the Kaplan-Meier method. Univariate and multivariate analyses of survival were performed using the Cox proportional hazards model.
RESULTS: After a median follow-up of 12 months (range, 3-31 months), no instances of ≥Grade 4 RP was documented, and clinically severe (Grade 3) RP occurred in 5.8% of the patients. 2 (3%) patients developed a late severe (≥Grade 3) symptomatic RF. No specific pattern of CT lung injury was demonstrated, in both acute and late settings. Median overall survival (OS) and progression-free survival (PFS) for the entire population were 30.8 and 14.1 months, respectively. At multivariate analysis (MVA), BED10 ≥ 100 Gy and KPS ≥ 90 emerged as significant prognostic factors for OS (p = 0.01 and p = 0.001, respectively), and BED10 ≥ 100 Gy for PFS (p = 0.02).
CONCLUSION: Our findings show that HHT adjusted for tumour location and/or target volume is an effective treatment with an acceptable toxicity profile in patients who are medically inoperable with lung tumours and is not associated with a specific pattern of lung injury. Therefore, it can represent a viable option when conventional stereotactic ablative radiotherapy facilities are not available. Advances in knowledge: The present study is among the largest series addressing the role of HHT for inoperable lung tumours. This technique is safe and effective and is not associated with a specific pattern of lung injury, at least at early and average time points.
引用
- Arcangeli S, Falcinelli L, Bracci S, et al. Treatment outcomes and patterns of radiologic appearance after hypofractionated image-guided radiotherapy delivered with helical tomotherapy (HHT) for lung tumours. Br J Radiol. 2017. PMID: 28256158. doi:10.1259/bjr.20160853
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。